Just had the following from Lotus. We will have to wait and see what happens.
This email is to provide a key update regarding all orders placed since Friday, 15th August.
If you have received your full order, please accept my apologies and disregard this message.
As we are all aware, the recent price change announcement by Eli Lilly has sent the industry into a state of unprecedented demand.
First and foremost, if you have received an order received email from us, please rest assured that your order is secure and we are working diligently to fulfill it as quickly as possible.
Due to this exceptional volume, our primary pharmacy, CloudRx, has informed us that they have reached their processing capacity. As such, some orders have been sent to our trusted partner pharmacy, SignatureRX, to fulfill.
While this may cause a small delay, we want to assure you that all confirmed orders will be fulfilled. You will receive the exact same brand name product: Mounjaro, manufactured by Eli Lilly. SignatureRX is a larger company and they have plenty of Mounjaro stock to handle the increased demand.
Once your order has been processed, you will receive tracking information via email. We expect those who have not yet received tracking information to receive it in the next 1-2 days.
For Patients with Bundle Orders
We have been informed that for some patients who placed a bundle order, one of the pens may have been dispatched by CloudRx before they reached capacity. As above, the remainder of your order has been sent directly to and will be fulfilled by SignatureRX.
Holiday & Delivery Concerns
Some customers have advised that they are leaving for holiday soon and are concerned about missing their delivery. Should you wish to delay delivery, we can place your order on hold until you return. However, please be aware that we would need to dispatch your order before the 1st September price change takes effect.
Please also note that we are still limiting orders to existing customers only at this time, with a 4-pen limit per customer.
We will continue to provide updates in due course. Should you require an urgent update, please email us at [email protected]. Our team is working through all emails and contact page queries as quickly as possible and we appreciate your patience.
Thank you for your understanding.
Kind regards,
Kyle Jones
Managing director